ClinicalTrials.gg
RecruitingNCT07119216Updated Nov 19, 2026

The iPeer2Peer Mentorship Program for Young Adults With Heart Disease

An interventional study of Peer Mentorship in Heart Failure, Mentorship and Peer Support, sponsored by Samantha Anthony. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Samantha Anthony · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 454 studies in Heart Failure with a site in Canada — 77 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Canada.

Planned enrollment
255th of 362
80 · median 226
Started
2026
with 11 others
No phase
162 of 454
31 open now
Primary completion
2027-12
later than 63 of 98 live
Registered
439th of 454
by date

Among the 454 studies in Heart Failure with a site in Canada, this one is the 255th largest by planned enrollment of the 362 interventional ones that give a count, is one of 12 that started in 2026, is one of 162 with no phase, reaches primary completion later than 63 of the 98 other live ones, and was the 439th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

77 of the 454 studies in Heart Failure with a site in Canada are open now. Recruiting first, the newest first:

71 more — sign in →

All 77 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Heart Failure with a site in Canada, or all of them as a file.
02

Study summary

Young adults with heart failure, including those who have undergone a heart transplant, experience considerable psychosocial stressors associated with living with a chronic illness, including heightened levels of anxiety and depression, and poor health-related quality of life compared to 'healthy' peers. Psychosocial challenges during young adulthood are especially concerning as this life stage represents a unique transitional period for fostering self-identity, friendships, mastery, and decision-making competencies. As young people with heart failure transition into adult healthcare systems, they take on greater personal responsibility due to their increasing independence and involvement in care decisions, and require more support and resources to live longer, healthier lives. Peer support provided by a person with a similar experience has been found to improve disease self-management and psychosocial health outcomes in pediatric healthcare.

An established, online mentorship program, iPeer2Peer (iP2P), will be employed through a pilot feasibility waitlist randomized controlled trial with repeated measures across five sites. Sixty mentees will be recruited and randomized into intervention and control groups. Thirty mentees in the intervention group will be matched 1:1 with 20 trained mentors. These pairings will connect over 12 weeks through video calls and text messaging to provide peer support to improve self-management and psychosocial health outcomes.

Read the detailed description

Primary Objective: to evaluate the feasibility of the iP2P program in terms of participant: (a) recruitment and withdrawal rates, (b) adherence with the program, (c) perceptions regarding the acceptability and level of engagement in the iP2P program, and (d) perceptions of barriers and enablers of the iP2P program.

Secondary Objective: to explore the iP2P program's impact on preliminary psychosocial outcomes in:

i.Mentees- (a) disease self-management, (b) perceived social support, (c) emotional distress, (d) resiliency and (e) hope; ii.Mentors- (a) perceived social role satisfaction, (b) emotional distress, and (c) hope.

A waitlist pilot RCT allows for an effective comparison of the study intervention with a control group receiving standard of care while not disadvantaging the control group who will have the option of participating in the intervention following the completion of the trial.

Up to 80 participants will be enrolled in this study at five sites: Mazankowski Alberta Heart Institute (Edmonton), St. Boniface Hospital (Winnipeg), Toronto General Hospital (Toronto), the University of British Columbia Division of Cardiology - Vancouver General Hospital and St Paul's Hospital (Vancouver).

We expect 20 adult mentors and 60 young adult mentees will be enrolled across these sites, with 4-6 mentors and about 10-15 mentees per site. The mentees will be randomized to the experimental (iP2P program; n=30) or control (waitlist; n=30) group. Mentees assigned to the waitlist will receive the iP2P program once all outcome measures are complete.

All mentees will be asked to participate in semi-structured individual interviews at baseline (ME T1) and and all mentees in the intervention group will be asked to participate in semi-structured interviews at 12 weeks - immediately post-intervention (ME T2). Interviews will be conducted by an interviewer trained in qualitative methods by telephone, in-person or virtually via the PHIPA-compliant version of Zoom or Microsoft Teams (depending on participants' preference), at a time that is convenient for the participant. Interviews will be guided by a semi-structured interview guide. ME T1 interviews will aim to assess motivations for participation, hopes and expectations, and preferences around mentor characteristics; and ME T2 interviews will aim to assess the primary outcomes evaluating feasibility.

All mentors will be asked to participate in a focus group/semi-structured interview prior to mentor training (MR T1) and study end (MR T2). MR T1 focus groups/interviews will aim to assess motivations for participation and hopes and expectations, and MR T2 focus groups/interviews will aim to assess the primary outcomes evaluating feasibility. Focus groups/interviews will be conducted by an interviewer trained in qualitative methods. Focus groups/interviews will be conducted on a mutually agreed upon date and over the internet via a web-based video communication program (e.g., PHIPA-compliant version of Zoom or Microsoft Teams).

The semi-structured individual interviews and focus groups will be audiotaped, transcribed and analyzed using qualitative descriptive approach using thematic and content analysis.

03

Conditions studied

  • Heart Failure
  • Mentorship
  • Peer Support
  • Peer Support and Chronic Disease
  • Young Adults
  • Cardiomyopathies
  • Heart Transplant Recipient
  • Fontan Procedure

Keywords

  • heart failure
  • mentorship
  • peer support
  • young adult
  • heart disease
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Peer Mentor inclusion criteria: (a) heart disease patients, (b) at least three months post-diagnosis, (c) between the ages of 26-35 years old, (d) nominated by a member of their healthcare team as a good candidate to act in the mentor role based on maturity and emotional stability (e.g., good communication skills, positive adaptation and adjustment, strong support network), (e) willingness to commit to virtual peer mentor training, (f) able to speak and read English, and (g) access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software.
  • Peer Mentee inclusion criteria: (a) heart disease patients, (b) between the ages of 18-25 years old, (c) able to speak and read English, and (d) access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software.

Heart disease patients include:

  • Patients with any past or present heart failure
  • Patients with cardiomyopathy seen at least 2 times a year
  • Patients who have undergone a Fontan procedure
  • Patients who have undergone a heart transplant

Exclusion criteria

Exclusion Criteria:

  • Mentor and mentee exclusion criteria include: (a) Significant cognitive impairments as assessed by a qualified healthcare provider (HCP), (b) have a diagnosis of an active psychological disorder (e.g.: Major Depressive Disorder, etc.; determined through chart review by a qualified HCP) likely to influence assessment of health-related quality of life and/or interfere with their ability to manage their heart disease care regimen, and (c) are participating in other peer support or self-management interventions.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention group

    In addition to their standard medical care, mentees in the experimental group will receive mentorship and support via the iP2P program. Trained mentors will provide information and support to mentee participants to encourage participation in self-management skill-building tailored to their needs. Each mentor will work with no more than two mentees at once for the study. Efforts will be made to pair mentors and mentees who share similar characteristics (e.g., similar disease severity, symptom profile, treatment regimen experiences, caregiver role, sex/gender, geographic area of residence). To ensure safety, a member of the research team will monitor all calls and messaging conversations as well as intervene in any potential safety concerns (e.g., discussion of suicidal ideation) or inappropriate behavior (e.g. bullying).

    Behavioral: Peer Mentorship

  • No intervention
    Waitlist control

    The control group will receive standard care without the iP2P intervention. The control group will be offered the iP2P intervention after completion of all outcome measures for a period of 12 weeks with the same research team support.

Interventions

  • BehavioralPeer Mentorship

    The iPeer2Peer intervention is a peer support mentorship program that will provide modelling and reinforcement by pre-screened and trained peer mentors to the mentees. The mentorship program will encourage mentees to develop and engage in self-management and transition skills and support the participants; practice of these skills. The mentors will provide information and support to mentee participants via 5-10 calls (using WhatsApp) of 20-30 minute durations and text messaging (using WhatsApp) for 12 weeks to encourage participation in self-management skill building tailored to their needs.

    Also known as: Peer mentoring, Peer support

06

What researchers measure

Primary outcomes

  1. Recruitment and withdrawal rates

    (a) Recruitment rates (more than 70%) and withdrawal rates (less than 15%) as calculated using data recorded in participant recruitment log.

    Time frame: Baseline to study completion

  2. Level of engagement

    Measured via semi-structured interviews or focus groups.

    Time frame: 12 weeks

  3. Adherence

    More than 80% rate of completion of at least five audio or video calls over 12 weeks and 100% rate of completion of all online outcome measures as calculated using data recorded in participant program tracking log.

    Time frame: 12 weeks

  4. Acceptability

    When the innovation is agreeable, palatable or satisfactory. Measured via focus groups or semi-structued interviews.

    Time frame: 12 weeks

  5. Barriers and enablers

    Measured via semi-structued interviews or focus groups.

    Time frame: 12 weeks

Secondary outcomes

  1. Perceived social role satisfaction (Mentors)

    Measured by the PROMIS Satisfaction with Social Roles and Activities

    Time frame: Baseline to study completion, an average of 1 year

  2. Emotional distress (Mentors)

    Measured by the General Anxiety Disorder-7 and the Patient Health Questionnaire Depression Scale

    Time frame: Baseline to study completion, an average of 1 year

  3. Hope (Mentors)

    Measured by the Adult Hope Scale

    Time frame: Baseline to study completion, an average of 1 year

  4. Disease self-management (Mentees)

    Measured by the Partners in Health Scale

    Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion

  5. Percevied social support (Mentees)

    Measured by the Multidimensional Scale of Perceived Social Support

    Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion

  6. Emotional distress (Mentees)

    Measured by the General Anxiety Disorder-7 and the Patient Health Questionnaire Depression Scale

    Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion

  7. Resiliency (Mentees)

    Measured by the Brief Resilience Scale

    Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion

  8. Hope (Mentees)

    Measured by the Adult Hope Scale

    Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 14 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 13, 2025
StartActual
Oct 20, 2026was Sep 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
The Hospital for Sick Children is now Recruiting
Nov 19, 2026
Start date
Sep 2025→Oct 20, 2026 (actual)
Nov 19, 2026
Sponsor
Collaborators added: Mazankowski Alberta Heart Institute·Toronto General Hospital·St. Paul's Hospital, Canada·St. Boniface Hospital
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    The Hospital for Sick Children is now Recruiting
    Start date Sep 2025→Oct 20, 2026 (now actual)
    Sponsor Collaborators added: Mazankowski Alberta Heart Institute·Toronto General Hospital·St. Paul's Hospital, Canada·St. Boniface Hospital
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07119216
Lead sponsor
Samantha Anthony
Collaborators
Heart and Stroke Foundation of Canada, Mazankowski Alberta Heart Institute, Toronto General Hospital, St. Paul's Hospital, Canada, St. Boniface Hospital
Responsible party
Samantha Anthony (Health Clinician Scientist, The Hospital for Sick Children) — Sponsor-investigator
First posted
Aug 13, 2025
Start date
Oct 20, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Samantha Anthony
Contact
samantha.anthony@sickkids.ca
416-813-7654 ext. 303126

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion